Capricor Therapeutics (CAPR) Raised to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Capricor Therapeutics (NASDAQ:CAPR) from a hold rating to a buy rating in a research note issued to investors on Tuesday morning. Zacks Investment Research currently has $2.00 price objective on the biotechnology company’s stock.

According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “

Separately, HC Wainwright reissued a buy rating and set a $8.60 target price (up previously from $6.50) on shares of Capricor Therapeutics in a research report on Friday, January 26th.

Capricor Therapeutics (NASDAQ CAPR) traded down $0.04 during midday trading on Tuesday, reaching $2.00. 621,900 shares of the company’s stock were exchanged, compared to its average volume of 660,068. The stock has a market cap of $52.45, a P/E ratio of -3.03 and a beta of -3.90. Capricor Therapeutics has a 1-year low of $0.63 and a 1-year high of $4.25.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Brown Advisory Inc. purchased a new position in Capricor Therapeutics during the 4th quarter valued at about $1,796,000. Virtu KCG Holdings LLC increased its position in Capricor Therapeutics by 571.9% during the 2nd quarter. Virtu KCG Holdings LLC now owns 179,301 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 152,614 shares during the period. Belpointe Asset Management LLC purchased a new position in Capricor Therapeutics during the 3rd quarter valued at about $249,000. Jane Street Group LLC purchased a new position in Capricor Therapeutics during the 3rd quarter valued at about $190,000. Finally, Wells Fargo & Company MN purchased a new position in shares of Capricor Therapeutics in the 3rd quarter worth approximately $107,000. 4.05% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Capricor Therapeutics (CAPR) Raised to Buy at Zacks Investment Research” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Get a free copy of the Zacks research report on Capricor Therapeutics (CAPR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply